O ukexilu ua kusaka o uhaxi ua izavu, u bhinga kuijiia se o uhaxi ua bhonzo mba kana.
O ukexilu ua kusaka u tena ku kuatekesa:
1. Ku bhanga pelasá: O athu ene mu sola o ukexilu iú phala ku saka o uhaxi ua izavu.
O dotolo u katula o kijimbu ni mbandu ia uôngo iala ku mbandu ia uôngo.
2. Milongo phala ku saka o uhaxi ua izavu: O milongo íii, i jibha o ji célula ja uhaxi ua izavu.
O milongo íii a tena ku i bhana ni lusolo mba ku i ta mu milongo ia mukuá.
3. Milongo phala ku sosolola o uhaxi: O milongo íii, i jibha o ji célula ja uhaxi.
O milongo íii a tena ku i bhana mu phutu, mba ku i nua mu kanu.
4. Milongo phala ku kuatekesa o ji célula ja câncer ku kula kiambote: O milongo íii phala ku kuatekesa o ji célula ja câncer ku kula kiambote.
O milongo íii, ene mu i bhanga phala ku saka uhaxi ua izavu.
5. O milongo íii i kuatekesa o mukutu uetu ku bhânga ni ji célula ja câncer.
O milongo íii, ene mu i bhanga phala ku saka uhaxi ua izavu.
6. Milongo phala ku saka o uhaxi ua izavu: O milongo íii, i jibha o ji célula ja uhaxi.
O milongo íii, ene mu i bhanga phala ku saka o uhaxi ua izavu.
7. O milongo íii, a ixana proton therapy: O milongo íii, a i bhanga ni kikuatekesu kia ji proton, mu veji dia ji radiação.
O milongo íii, ene mu i bhanga phala ku saka o uhaxi ua izavu.
8. Ku tokuesa: O jihaxi a tena ku xikina ku a saka mu ukexilu uéngi.
Kima kiambote kuzuela ni dotolo ia lungu ni ukexilu uambote ua ku saka o uhaxi iú, mukonda o ukexilu uambote ua ku saka, u bhinga kuijiia o uhaxi ua muthu.
Chen JH, Wu J, Xu Q: The emerging treatment landscape of targeted therapy in non-small-cell lung cancer. Signal Transduct Target Ther. , 4 (): 61.
Furuse K: [Photodynamic therapy of centrally located early-stage lung cancer]. Gan To Kagaku Ryoho. 1996, 23 (1): 27-30.
Gálffy G: [From rare mutations to classical ones, inhibition of signaling pathways in non-small cell lung cancer]. Magy Onkol. 2020, 64 (3): 196-204.
Magalhães M, Alvarez-Lorenzo C, Concheiro A, Figueiras A, Santos AC, Veiga F: RNAi-based therapeutics for lung cancer: biomarkers, microRNAs, and nanocarriers. Expert Opin Drug Deliv. 2018, 15 (10): 965-982.
Kataoka M, Fujiwara T, Tanaka N: [Gene therapy for lung cancer]. Nihon Geka Gakkai Zasshi. 2002, 103 (2): 244-9.
Jin C, Yang B: A Case of Delayed Diagnostic Pulmonary Tuberculosis during Targeted Therapy in an EGFR Mutant Non-Small Cell Lung Cancer Patient. Case Rep Oncol. , 14 (1): 659-663.
Wang Y, Liu Q, Chen H, You J, Peng B, Cao F, Zhang X, Chen Q, Uzan G, Xu L, Zhang D: Celastrol improves the therapeutic efficacy of EGFR-TKIs for non-small-cell lung cancer by overcoming EGFR T790M drug resistance. Anticancer Drugs. 2018, 29 (8): 748-755.
['Kitendelesu:']
['O kijimbuete kiki, phala ku longa ngó, ki kiene mu bhana milongi ia lungu ni sauidi.']
['O milongi íii, ka tokala ku i tumbula phala ku saka uhaxi, mba ku saka mauhaxi a mukuá.']
['Mu kifika, o ji komputadolo jene mu kuatekesa o athu kuijiia o ima ia lungu ni uhaxi, ki ji tena ku jimbulula kiambote o maka.']
['Sota kikuatekesu kia dotolo iê mba muthu ua mukuá uala ni uhete ua ku saka mauhaxi. Kana ku jimba o itendelesu ia dotolo mukonda dia milongi i ua tange mu kijimbuete kiki. Se ua mesena kikuatekesu, xinda ku muxinda ua 112, mba ndé mu inzo ia ku saka ia zukama.']
['Iala ni Kikutu ni Jinguvulu ja Jixi Jengi']
['O Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (o DMCA) i bhana ku athu ala ni ufolo ua ku soneka, o ima ia mona mu Internete, i bhukumukina o ufolo uâ ua ku soneka. ']
['Se eie u xikina ni kidi kioso kuila o milongi mba milongi i ua mu tanga mu kijimbuete kietu kia internete, mba mu ima ia mukuá, ia mu bhukumukina o itumu iê, eie (mba o muthu u ua mu tumina) u tena ku tu tumikisa mukanda ni ku tu bhinga phala ku katula o milongi mba milongi i ua mu tanga mba ku fidisa o muthu ku i tanga.']
['O ngolokela a tokala ku i tumikisa mu mukanda ni mu kijimbuete kia i-me-le (Tala o mbandu "Utuameni ua Ijimbuete") ].']
['O DMCA i bhinga kuila o njimbu iê ia lungu ni ku bhukumukina o itumu ia ku tokala, i kala ni milongi íii: (1) kijimbuluilu kia kikalakalu kia tokala ku kitumu kia ku tokala; (2) kijimbuluilu kia milongi ia ku tokala ni milongi i tua tokala ku sanga; (3) o ijimbuete iê, ni ijimbuete ia mutelembe uê; (4) ni izuelu i ua zuela kuila eie u xikina ni kidi kioso kuila o milongi ia ku tokala, ki i tokala ku ngana ia tokala, mba ku mukunji uê, mba ku kitumu kioso-kioso; ']
['(5) O kijimbuete kiê, ni kijimbuete kia ku tangela kuila o milongi iala mu kijimbuete kiki ia kidi, ni kuila eie uala ni kutena kua ku langa o ima ia ku tokala;']
['O kijimbuete kiki, ki tena ku kala ni kidimbu kiê, mba kijimbuete kia muthu ua mu tumina o ku ki jikula.']
['Se ku soneka o ima ioso íii, o ku tokuesa o maka mê kua-nda laleka.']
['Kuzuela ni Muthu']
['Tua ku dióndo, tu tumikise njimbu ni ibhuidisu mba jindunge.']
How to treat lung cancer?
The treatment for lung cancer depends on several factors, including the stage of the cancer, the type of lung cancer, and the patient's overall health.
Some common treatment options include:
1. Surgery: This is often the preferred treatment for early-stage lung cancer.
The surgeon removes the tumor and a small portion of healthy tissue around it.
2. Radiation therapy: High-energy radiation is used to kill cancer cells and shrink tumors.
It can be used alone or in combination with other treatments.
3. Chemotherapy: This treatment uses drugs to kill cancer cells.
It can be given intravenously or or orally, and is often used in combination with other treatments.
4. Targeted therapy: This treatment targets specific genes or proteins that contribute to the growth and survival of cancer cells.
It is often used for advanced or metastatic lung cancer.
5. Immunotherapy: This treatment helps the immune system recognize and attack cancer cells.
It is often used for advanced or metastatic lung cancer.
6. Photodynamic therapy: This treatment uses a light-activated drug to kill cancer cells.
It is often used for early-stage lung cancer.
7. Proton therapy: This is a type of radiation therapy that uses protons instead of x-rays to deliver radiation to the tumor.
It is often used for early-stage lung cancer.
8. Clinical trials: Patients may be eligible to participate in clinical trials testing new treatments or combinations of treatments.
It is important to discuss the best treatment options with a healthcare team, as the most effective treatment plan will depend on the individual's specific situation.
Disclaimer: medical
This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.
The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.
Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.
Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.
Disclaimer: copyright
The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.
['O ku']
['O BioMedLib i kalakala ni ji komputadolo phala ku bhanga ibhuidisu ni itambuijilu.']
['Tua mateka ni 35 a mazunda a madivulu a lungu ni sauidi mu internete, ni madivulu a mukuá a ubhe.']
['Tanga o mbandu "Referências" ni mbandu "Disclaimer".']
